<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544280</url>
  </required_header>
  <id_info>
    <org_study_id>2018-18 mai-217</org_study_id>
    <nct_id>NCT04544280</nct_id>
  </id_info>
  <brief_title>Effect of Repeated Injections of Higher Doses of Botulinum Toxin on Lower Limb of Spastic Hemiplegic Patients on Gait.</brief_title>
  <official_title>Évaluation de l'Effet d'Injections répétées de Hautes Doses de Toxine Botulique Dans le Membre inférieur de Sujets cérébrolésés Spastiques Sur Les paramètres Fonctionnels et biomécaniques de Marche</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To show that repeated injections of higher doses of botulinum toxin are significantly&#xD;
           more effective than the injection of unique, lower doses, on gait function.&#xD;
&#xD;
        2. To describe the effect of repeated injections of botulinum toxin on the muscle structure&#xD;
           in terms of volume, fat accumulation and fibrosis, by means of MRI studies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. A prospective, interventional, multi-centre, open-labeled study will be carried out.&#xD;
           Sixty stroke patients will be recruited (from the Rehabilitation Ward of Cliniques&#xD;
           Universitaires Saint-Luc (UCLouvain), or Centre Hospitalier Universitaire de Mont&#xD;
           Godinne (UCLouvain), or in the out-patients clinic), if they have an indication for&#xD;
           focal chemical denervation (by botulinum toxin injections) to treat lower limb&#xD;
           hyper-resistance (spasticity).&#xD;
&#xD;
           Inclusion criteria: adults (&gt;18 years old), hemiparesis secondary to stroke, date of&#xD;
           stroke&gt;3 months ago, lower limb hyper-resistance responsible of gait impairment, focal&#xD;
           chemical denervation indication, ability to walk on a treadmill.&#xD;
&#xD;
           Exclusion criteria: aphasia or major cognitive impairments limiting the functional&#xD;
           evaluation, neurological or orthopedic affections interfering with the studied lower&#xD;
           limb's function, BONT injections on the lower limb during the last 3 months,&#xD;
           contraindication to BONT injections (underlying neuromuscular disease) and no&#xD;
           contraindication to undergo an MRI study.&#xD;
&#xD;
           Patients will benefit from 3 sessions of botulinum toxin (Xeomeen) injections at 3&#xD;
           months intervals. During the first session, 400 U of Xeomeen will be injected in the&#xD;
           lower limb of the patient (and upper limb, if needed). During the second session, 600U&#xD;
           of Xeomeen will be injected and during the third session, 800Units of Xeomeen will be&#xD;
           injected (in the lower limb of the patient-and upper limb, if needed-). The injections&#xD;
           will be based on the clinical evaluation carried out by one of the investigators, who&#xD;
           are medical doctors, specialized in Physical and Rehabilitation Medicine and have&#xD;
           experience with hyper-resistance treatment with botulinum toxin.&#xD;
&#xD;
           Patients will be evaluated just before, a month later and 3 months after each injection&#xD;
           session. Functional evaluations are based on the ICF model. Impairment will be evaluated&#xD;
           by the clinical examination (range of motion -ROM- with a hand goniometer, MAS and&#xD;
           Tardieu scale for spasticity, Fugl-Meyer test for motor control)20; by functional&#xD;
           evaluations (10 meters walk test, 6 minutes walk test, timed up and down the stairs&#xD;
           test, Timed Up and Go Test) and by a 3D-Quantified Gait Analysis. The limitations in&#xD;
           activities of daily life will be evaluated by means of the ABILOCO questionnaire.&#xD;
           Quality of life (QoL) will be evaluated with the French version of the Short-Form Health&#xD;
           Survey SF-3624.&#xD;
&#xD;
        2. To describe the effect of repeated injections of botulinum toxin (Xeomeen) on the muscle&#xD;
           structure in terms of volume, fat accumulation and fibrosis, a lower limb MRI will be&#xD;
           performed before, 1-3 days and 1 month after the 1st Xeomeen injection, and 1 month&#xD;
           after the 3rd BONT injection, for 4 MRI studies per patient. Twenty hemiplegic subjects&#xD;
           will be recruited. They will participate to the complete study protocol, as described&#xD;
           for our first objective. Inclusion and exclusion criteria will be the same as previously&#xD;
           described.&#xD;
&#xD;
      Statistical analysis: The effects of treatment on continuous variables will be assessed by a&#xD;
      one-way (time) repeated-measures analysis of variance (Anova). Ordinal data will be assessed&#xD;
      by a non-parametric analysis. A Chi2 test will be used to compare the distributions of&#xD;
      qualitative variables. Testing will be performed with a p-value &lt;0,05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2018</start_date>
  <completion_date type="Anticipated">September 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective, interventional, multi-centre, open-labeled study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temporo-spatial parameters of gait</measure>
    <time_frame>7-9 months</time_frame>
    <description>Improvement of temporo-spatial parameters of gait as assessed by quantified gait analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Segmental kinematics of gait</measure>
    <time_frame>7-9 months</time_frame>
    <description>Improvement of segmental kinematics of gait as assessed by quantified gait analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energetic parameters</measure>
    <time_frame>7-9 months</time_frame>
    <description>Improvement of energetic parameters of gait as assessed by quantified gait analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle structure</measure>
    <time_frame>7-9 months</time_frame>
    <description>Modification of muscle structure (volume, presence of fatty and fibrotic tissue) after repeated botulinum toxin injections as evaluated by MRI imaging.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xeomin Injectable Product</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hemiparesis secondary to stroke, date of stroke&gt;3 months ago, lower limb hyper&#xD;
             resistance responsible of gait impairment, focal chemical denervation indication,&#xD;
             ability to walk on a treadmill&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  aphasia or major cognitive impairments limiting the functional evaluation,&#xD;
             neurological or orthopedic affections interfering with the studied lower limb's&#xD;
             function, botulinum toxin injections on the lower limb during the last 3 months,&#xD;
             contraindication to botulinum toxin injections (underlying neuromuscular disease) and&#xD;
             no contraindication to undergo an MRI study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clara SELVES, MD</last_name>
    <phone>+327648646</phone>
    <email>clara.selves@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gaëtan STOQUART, MD, PhD</last_name>
    <phone>+327641649</phone>
    <email>gaetan.stoquart@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaire Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara SELVES, MD</last_name>
      <phone>+327648646</phone>
      <email>clara.selves@uclouvain.be</email>
    </contact>
    <contact_backup>
      <phone_ext>SELVES</phone_ext>
      <email>clara.selves@uclouvain.be</email>
    </contact_backup>
    <investigator>
      <last_name>Clara SELVES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaëtan STOQUART, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires UCL Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry DELTOMBE, MD, PhD</last_name>
      <email>therry.deltombe@uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Corriveau H, Hébert R, Raîche M, Dubois MF, Prince F. Postural stability in the elderly: empirical confirmation of a theoretical model. Arch Gerontol Geriatr. 2004 Sep-Oct;39(2):163-77.</citation>
    <PMID>15249153</PMID>
  </reference>
  <reference>
    <citation>Hirvensalo M, Rantanen T, Heikkinen E. Mobility difficulties and physical activity as predictors of mortality and loss of independence in the community-living older population. J Am Geriatr Soc. 2000 May;48(5):493-8.</citation>
    <PMID>10811541</PMID>
  </reference>
  <reference>
    <citation>Brandstater ME, de Bruin H, Gowland C, Clark BM. Hemiplegic gait: analysis of temporal variables. Arch Phys Med Rehabil. 1983 Dec;64(12):583-7.</citation>
    <PMID>6661021</PMID>
  </reference>
  <reference>
    <citation>Pinzur MS, Sherman R, DiMonte-Levine P, Trimble J. Gait changes in adult onset hemiplegia. Am J Phys Med. 1987 Oct;66(5):228-37.</citation>
    <PMID>3324770</PMID>
  </reference>
  <reference>
    <citation>Olney SJ, Griffin MP, McBride ID. Temporal, kinematic, and kinetic variables related to gait speed in subjects with hemiplegia: a regression approach. Phys Ther. 1994 Sep;74(9):872-85.</citation>
    <PMID>8066114</PMID>
  </reference>
  <reference>
    <citation>Stoquart G, Detrembleur C, Lejeune TM. The reasons why stroke patients expend so much energy to walk slowly. Gait Posture. 2012 Jul;36(3):409-13. doi: 10.1016/j.gaitpost.2012.03.019. Epub 2012 May 1.</citation>
    <PMID>22555062</PMID>
  </reference>
  <reference>
    <citation>Caty GD, Detrembleur C, Bleyenheuft C, Deltombe T, Lejeune TM. Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait. Stroke. 2008 Oct;39(10):2803-8. doi: 10.1161/STROKEAHA.108.516153. Epub 2008 Jul 17.</citation>
    <PMID>18635841</PMID>
  </reference>
  <reference>
    <citation>Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqué B, Simon O, Rochford ET, Dressler D, Simpson DM; TOWER study investigators. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017 Apr 4;88(14):1321-1328. doi: 10.1212/WNL.0000000000003789. Epub 2017 Mar 10.</citation>
    <PMID>28283596</PMID>
  </reference>
  <reference>
    <citation>Minamoto VB, Suzuki KP, Bremner SN, Lieber RL, Ward SR. Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections. Muscle Nerve. 2015 Oct;52(4):649-57. doi: 10.1002/mus.24576. Epub 2015 Jun 30.</citation>
    <PMID>25598004</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>botulinum neurotoxin</keyword>
  <keyword>spasticity</keyword>
  <keyword>hyper-resistance</keyword>
  <keyword>MRI</keyword>
  <keyword>muscle structure</keyword>
  <keyword>gait rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

